Listar por tema "Risk Management"

Ordenar por:Orden:Resultados:

  • Biological and nonbiological complex drugs for multiple sclerosis in Latin America: Regulations and risk management 
    Carrá, A.; Macías Islas, M.A.; Tarulla, A.; Bichuetti, D.B.; Finkelsztejn, A.; Dadalti Fragoso, Y.; Árcega-Revilla, R.; Cárcamo Rodríguez, C.; Durán, J.C.; García Bonitto, J.; León, Rosalba; Oehninger Gatti, C.; Orozco, G.; Vizcarra-Escobar, Darwin (Taylor and Francis, 2015)
    Biological drugs and nonbiological complex drugs with expired patents are followed by biosimilars and follow-on drugs that are supposedly similar and comparable with the reference product in terms of quality, safety and ...
  • Is Unplanned PICU Readmission a Proper Quality Indicator? A Systematic Review and Meta-analysis 
    Prutsky, Gabriela J.; Padhya, Dipti; Ahmed, Ahmed T.; Almasri, Jehad; Farah, Wigdan H.; Prokop, Larry J.; Murad, M. Hassan; Alsawas, Mouaz (American Academy of Pediatrics, 2021)
    CONTEXT: Unplanned PICU readmissions within 48 hours of discharge (to home or a different hospital setting) are considered a quality metric of critical care. OBJECTIVE: We sought to determine identifiable risk factors ...

Buscar en el Repositorio

Listar

Panel de Control